Feasibility and Safety of NeuroFlo in Stroke Patients Receiving Tissue Plasminogen Activator
NCT ID: NCT01006993
Last Updated: 2010-03-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
22 participants
INTERVENTIONAL
2007-05-31
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)
NCT00119717
Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke
NCT06781385
TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion
NCT01654445
Early Mobilization of Ischemic Stroke Patients Within 24-hours After Intravenous-Tissue Plasminogen Activator (IV-tPA)
NCT01331200
Biomarkers of Acute Stroke in Clinic
NCT03897478
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NeuroFlo Treatment
NeuroFlo catheter
NeuroFlo™ catheter 45 minute treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NeuroFlo catheter
NeuroFlo™ catheter 45 minute treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* NIHSS between 5-22
* Persistent clinical deficits following administration of rt-PA
Exclusion Criteria
* Aortic pathology
* Severe heart disease
* Other conditions the doctor will assess
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CoAxia
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CoAxia, Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
FASTFlo Steering Committee
Role: STUDY_DIRECTOR
Various
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alberta
Edmonton, Alberta, Canada
University of Western Ontario
London, Ontario, Canada
Trillium Health Centre
Mississauga, Ontario, Canada
University of Erlangen
Erlangen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Emery DJ, Schellinger PD, Selchen D, Douen AG, Chan R, Shuaib A, Butcher KS. Safety and feasibility of collateral blood flow augmentation after intravenous thrombolysis. Stroke. 2011 Apr;42(4):1135-7. doi: 10.1161/STROKEAHA.110.607846. Epub 2011 Feb 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CD-0258
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.